Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 14, 2009

Galapagos and Merck & Co. Expand Existing Metabolic Disease Alliance to Cover Atherosclerosis

  • Galapagos and Merck & Co. expanded their existing global collaboration in metabolic diseases to cover the development of new small molecule candidates against atherosclerosis. The original deal, signed in January, covered obesity and diabetes.

    The wider collaboration could see Galapagos’ research, regulatory, and sales milestone payments double to over E400 million, or roughly $596.03 million.

    Under terms of the expanded agreement, Galapagos will use its target discovery platform to identify and validate novel targets in all three indications. The company will also be responsible for the discovery of new drug candidates against these targets.

    Merck will have an exclusive option to license each candidate for clinical development and commercialization worldwide. Galapagos is eligible to receive royalties upon commercialization of any products covered under the agreement.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »